KPV Peptide Dosage Chart by Condition

This KPV peptide dosage chart covers the three most common goals: gut and IBD, skin and eczema, and general systemic inflammation. Doses are daily totals. Routes reflect where the inflammation lives, not personal preference.

Most protocols run 4 to 8 weeks. Start at 200 mcg/day for the first week, then increase to 500 mcg if well tolerated. The low-then-high ramp lets you confirm tolerance before committing to the full dose, and it costs nothing in efficacy because the research-backed range spans both numbers. For the full route-by-route breakdown, see the KPV dosage guide. For where KPV sits among other anti-inflammatory peptides, see peptides for inflammation.

Read the chart by goal, not by habit. A person with ulcerative colitis and a person with shoulder inflammation can run the same 300 mcg daily dose, yet one swallows it and the other injects it. The milligram figure is shared. The delivery is not. That single distinction prevents most of the disappointment people report with KPV, because a correctly dosed peptide sent to the wrong tissue simply underperforms.

Oral vs subcutaneous in one sentence: oral for anything inside the gut, subcutaneous for anything outside it.

KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the C-terminal tail of alpha-melanocyte-stimulating hormone (alpha-MSH), occupying positions 11 through 13. It carries the anti-inflammatory activity of the parent hormone but drops the receptor-binding region. That separation is the whole point.

Because KPV does not bind melanocortin receptors (MC1R, MC3R, MC5R), it produces no skin tanning or pigmentation at any dose, unlike full-length alpha-MSH or Melanotan II. The anti-inflammatory and the pigmentation functions of alpha-MSH live in different parts of the molecule, and KPV keeps only the first (Brzoska et al., 2008).

Inside the cell, KPV blocks NF-kB, the master switch for inflammatory gene transcription. Shutting that switch down lowers production of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory cytokines. The effect appears largely receptor-independent, which is why such a tiny peptide works at all.

KPV also modulates immune tone rather than suppressing it. It nudges macrophages from an inflammatory state toward a reparative one without disabling the body's ability to fight infection. That distinction matters for dosing decisions: KPV is not a corticosteroid and does not need tapering, and it does not blanket-suppress immunity the way systemic steroids do. The practical implication is a peptide that can run for weeks at a steady dose without the metabolic baggage that limits how long you can use stronger anti-inflammatories.

Its small size also helps. At roughly 341 daltons across three amino acids, KPV is among the smallest peptides used in this space, which contributes to both its oral absorption through PepT1 and its relative stability compared with larger peptides. For the full mechanism and benefits, see the KPV peptide profile.

The dose stays roughly constant. The goal decides the route, the timing, and the duration.

Oral and subcutaneous KPV use the same daily milligram range. The difference is destination, not dose size.

The common error is assuming injection is always stronger. For gut conditions it is not. Oral KPV places the peptide exactly where colitis occurs, and the PepT1 upregulation during inflammation creates a delivery advantage injection cannot copy (Dalmasso et al., 2008). For systemic targets the logic flips, and subcutaneous wins. Many users separate these by time of day as well, depending on goal.

Injectable KPV ships as a lyophilized powder that you reconstitute with bacteriostatic water before drawing a dose.

The math: add 2 mL bacteriostatic water to a 10 mg vial, which yields 5,000 mcg/mL. On a U-100 insulin syringe, every 0.1 mL equals 10 units.

Run your exact vial size through the peptide reconstitution calculator before drawing the first dose. Inject the water slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Never shake.

A worked example removes the guesswork. Say you want 300 mcg from that 5,000 mcg/mL solution. Divide 300 by 5,000 to get 0.06 mL, which is 6 units on a U-100 syringe. The arithmetic is always dose divided by concentration, then read the milliliter figure as units by multiplying by 100. Keeping the concentration round (5,000 mcg/mL) makes the units land on clean numbers.

Storage: refrigerate reconstituted KPV at 2 to 8 degrees Celsius and use within about 4 weeks. Do not freeze the solution, since freeze-thaw cycles can degrade peptide potency. Keep the vial out of direct light and away from heat. For full handling timelines, see how long reconstituted peptides last.

Most KPV problems come from route and handling errors, not dose size.

• Injecting for gut issues. Subcutaneous KPV skips the PepT1 self-targeting that makes oral effective for colitis and IBD. Use oral for the gut.
• Taking oral KPV with food. Dietary peptides compete for PepT1 binding. Dose on an empty stomach, 30 minutes before eating.
• Shaking the vial. Shaking can damage the peptide. Swirl gently to dissolve.
• Skipping the dose math. Eyeballing units leads to large errors. Confirm with the reconstitution calculator every time.
• Running it during an active infection. Damping inflammation mid-infection can be counterproductive. Review the peptide safety guide and a clinician first.
• Expecting overnight results. Gut benefits typically appear at 2 to 4 weeks, not days. For the broader dosing landscape, see the peptide dosage chart.